China's NMPA Accepts IND Application for Harbour BioMed's AI-Designed Obesity Antibody LET003
On November 18, 2026, Harbour BioMed said China's NMPA accepted the IND application for LET003, its first AI-enabled antibody drug candidate for obesity.
Read the full story at Unite.AI ↗
Timeline · 1 report
- 2026-11-19 00:26 · Unite.AI
Harbour BioMed’s AI-Enabled Obesity Antibody LET003 Has IND Accepted